Review Article

Functionally Improved Mesenchymal Stem Cells to Better Treat Myocardial Infarction

Zhi Chen,1 Long Chen,2 Chunyu Zeng,1 and Wei Eric Wang1

1Department of Cardiology, Daping Hospital, Third Military Medical University, 10 Changjiang Branch Road, Chongqing 400042, China
2College of Medicine, Soochow University, Suzhou 215123, China

Correspondence should be addressed to Wei Eric Wang; weiericwang@126.com

Received 21 May 2018; Revised 10 September 2018; Accepted 30 September 2018; Published 25 November 2018

Guest Editor: Myoung W. Lee

Copyright © 2018 Zhi Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Myocardial infarction (MI) is one of the leading causes of death worldwide [1–3]. Though pharmacotherapy, thrombolysis, coronary stent implantation, and coronary artery bypass grafting have been clinically used to treat MI and improve patients’ survival, these methods cannot fundamentally repair the damaged heart and restore heart function. Stem cell transplantation is considered as a promising method to treat MI and improve patients’ survival, these methods cannot fundamentally repair the damaged heart and restore heart function. Stem cell transplantation is considered as a promising way to treat MI, which has made significant progress in preclinical and clinical studies recently [4]. Stem cell candidates mainly include two categories: (1) pluripotent stem cells (embryonic stem cell and induced pluripotent stem cells) and their derivatives and (2) adult stem cells, including hematopoietic stem cells and mesenchymal stem cells (MSCs) [5]. MSCs are mesoderm-derived multipotent stromal cells that reside in embryonic and adult tissues, having the capacity for self-renewal, immune privilege, immunomodulation, and low tumorigenicity [6]. To date, MSCs have become the mostly practiced cell type in clinical trials for treating MI [7], due to the safety, multidifferentiation potential, nutritional activity, immunomodulatory properties, and abundant donor sources [6, 8]. MSCs have low immunogenicity due to the low expression of MHC II as well as the lack of expression of MHC I, which lead to immune tolerance allowing allogeneic transplantation [8].

However, the therapeutic effect of MSC transplantation is unsatisfactory. The increase in left ventricular systolic function (LVSF) of MI patients is only 3–10% with MSC transplantation [9]. Implanted cells do not survive for a long time. In fact, only about 3% of MSCs appeared in the marginal area of the infarct myocardium within 24 hours after systemic administration, and less than 1% of MSCs could survive for more than a week [5]. Recent studies have concluded that MSCs are very difficult to differentiate towards cardiomyocytes, and the benefits of MSC therapy mainly depend on its paracrine mechanism [10]. The key steps of the cell therapy procedures, such as donor selection, in vitro amplification, survival in a hostile transplantation microenvironment, migration, differentiation, and paracrine function, need to be optimized. Here, we review the strategies
of MSC modifications for optimizing the therapeutic potential of MSCs against MI.

2. Therapeutic Effect of MSCs against MI Injury

MSCs have the potential of self-renewal, proliferation, and multidifferentiation in an appropriate microenvironment [11]. MSCs exert a therapeutic effect on MI through direct differentiation into vessel cells (cardiomyocyte differentiation events are rare) and paracrine mechanism (which has been proved predominant) [10]. Transplanted MSC-derived endothelial cells and vascular smooth muscle cells can contribute to the new vessel formation [12–14]. MSC paracrine factors include protein cytokines such as vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF), miRNAs [15–17], and exosomes [18]. These factors can induce immunomodulation and anti-inflammatory effects, evidenced by inhibition of the activity of inflammatory mediators and regulation of the function of immune cells [19]. The factors can induce an antifibrotic effect by inhibiting the proliferation of fibroblasts, reducing the deposition of collagen and producing matrix metalloproteinases [20]. In addition, factors such as stromal cell-derived factor-1 (SDF-1), VEGF, and basic fibroblast growth factor (bFGF) have a strong proangiogenic effect, due not only to promotion of endothelial cell proliferation and migration but also to prevention of endothelial cells from apoptosis [8, 21].

The MSC-based treatments for MI have successfully entered phase I and phase II clinical trials. A meta-analysis comprising 34 randomized controlled trials (RCTs) with a total number of 2307 patients indicates that MI patients who received MSC transplantation showed a significantly improved cardiac function, a significant increase in the left ventricular ejection fraction (LVEF) (+3.32%), and a decrease in LV end-diastolic indexes (−4.48) and LV end-systolic indexes (−6.73) [22]. Another meta-analysis covering 28 RCTs with a total of 1938 STEMI patients shows that MSC treatment resulted in an improvement in long-term (12 months) LVEF of 3.15% [23]. A recent study also showed benefits of MSC transplantation on mechanical and clinical outcomes. The LVEF of MI patients with MSC treatment increased by 3.84%, and the effect was maintained for up to 24 months. Scar mass was reduced by −1.13, and the wall motion score index was reduced by −0.05 at 6 months after MSC treatment [24]. Clinical trials of MSC transplantation for treating MI are listed in Table 1. Though previous clinical trials have made some advances, optimizing the process of MSC transplantation is needed in preparing for the clinical phase III trials.

3. Strategies for Optimizing MSC-Based Therapy

MSCs can be obtained from various tissues such as bone marrow, fat, peripheral blood, lungs, muscle, placenta, umbilical cord blood, and dental pulp [40]. Bone marrow MSCs (BM-MSCs) are the most frequently investigated and tested in clinical trials. It is reported that MSCs from younger donors are more effective than those from older donors, indicating an age-dependent effect of MSC functions. The expressions of inhibitory kappa B kinase, interleukin-1a, and inducible nitric oxide synthase in the elderly donor’s MSCs were significantly decreased [15]. Previous studies showed that the expression of the pigment epithelium-derived factor (PEDF) was significantly increased in MSCs of aged mice compared with young mice. Knockout PDEF in aged MSCs can improve the therapeutic effect of MSCs [41]. These data suggest that using young MSCs for treating MI might be a more advisable option.

For cell number of MSC transplantation, ~10^5–10^7 MSCs were reported in diverse studies [42], but usually >1 × 10^7 cells were required in clinical trials given the low retention rate [43, 44]. Cell expansion in vitro is needed for about 1–3 months before implantation to obtain enough cell numbers [5]. However, cell aging and the loss of chemokine markers during amplification could reduce the cell survival and functions of MSCs in the transplantation microenvironment. Methods such as environmental preconditioning, cytokine or drug coculture, and gene modification may overcome these problems.

3.1. Preconditioning MSCs in Culture before Transplantation

3.1.1. Hypoxia Preconditioning. The peripheral area of MI is a typical site for preclinical MSC treatment. The oxygen partial pressure in the peripheral area generally does not exceed 1%, and hypoxia is a major cause of dysfunction and death of transplanted MSCs [45]. Hypoxia preconditioning in vitro (2–5% oxygen) can maintain homogeneity and differentiation potential, delay cell senescence process, and increase chemokine receptor expression of MSCs [46]. Hypoxia preconditioning is also proved to increase the paracrine activity of nonhuman primate MSCs [47]. Thus, MSCs with hypoxia preconditioning is more therapeutically effective against massive myocardium injury and does not increase the incidence of arrhythmia complications [48].

3.1.2. Hyperoxia or Hydrogen Peroxide Preconditioning. Hyperoxia pretreatment can also improve MSC efficacy by reducing the number of apoptotic cells. BM-MSCs were implanted into hypoxic tissues after hyperoxia (100% oxygen), and the apoptotic cells were significantly reduced (apoptotic score index determined by TUNEL assays reduced from 86.6% to 11.6%) [49]. In addition, sublethal hydrogen peroxide preconditioning attenuated oxidative stress-induced cell apoptosis. Pretreatment with 200 μmol/L H_2O_2 for 2 hours decreased MSC apoptosis. Compared with control MSCs, MSCs with H_2O_2 pretreatment better improved cardiac function and reduced myocardial fibrosis [50].

3.1.3. Thermal Preconditioning. MSCs were incubated with water bath at 42°C for 2 hours before transplantation can effectively reduce the oxide-induced apoptosis of MSCs and enhance cell survival. The mechanism may be related to the expression of heat shock proteins, which act as a molecular chaperone and indirectly promote cell survival by inhibiting the apoptosis pathway and resist oxidation stress [51].
3.1.4. Nutritional Deprivation Preconditioning. The transplantation microenvironment is poor in nutritional supply. Reducing energy requirements to allow MSCs to enter a relatively quiescent state helps them adapt to the upcoming low-energy environment. Serum deprivation for 48 hours could induce MSCs into a quiescent state and improve MSC survival rates. Compared with control, serum deprivation increased the survival rates by 3–4-fold after the third day and on the seventh day after transplantation [52].

3.1.5. Transient Adaptation Preconditioning. Although MSC itself is with low immunogenicity, the presence of immunogenic contamination in xenogeneic serum may result in acute rejection with the host immune system after MSC transplantation [53]. A two-stage culture strategy was developed to overcome this problem. In the first phase, the MSCs were isolated and expanded in the human platelet lysate or mixed allogeneic serum medium. Then, in the second stage, the expanded MSCs were cultured in the autologous serum. This transient adaptation in autologous serum may contribute to the expression of chemokine receptors and tissue-specific differentiation of amplified MSCs in vitro, which provides an efficient method for the immunological rejection [46].

### Table 1: Clinical trials of MSC transplantation for treating MI.

| Clinical trials | Phase | Dose (×10⁶) | Delivery route | Enrollment | Infarct scar | LVEF | Following up | Study | Reference |
|-----------------|-------|-------------|---------------|------------|-------------|------|--------------|-------|-----------|
| NCT00114452    | Phase 1 | 0.5/1.6/5 | IC            | 53         | n.a.        | ↑ ** | 6 m         | Hare et al. (2009) | [25]   |
| NCT00677222    | Phase 1 | 100        | IC            | 30         | n.a.        | ↑ *  | 4 m         | Penn et al. (2012) | [26]   |
| 2011AA020109   | Phase 1 | 3.08       | IC            | 43         | =           | ↑ *  | 12 m        | Gao et al. (2013)  | [27]   |
| U01 HL087318–04| Phase 1 | 150        | IC            | 65         | ↓ *         | ↑ ***| 12 m        | Traverse et al. (2014) | [28]   |
| NCT01234181    | Phase 1 | 100        | IC            | 22         | ↓ *         | ↑ *  | 12 m        | Hu et al. (2015)  | [29]   |
| NCT01087996    | Phase 1/2 | 20        | IM            | 30         | ↓ ***       | ↑   | 13 m        | Hare et al. (2012) | [30]   |
| U54HL081028    | Phase 1/2 | 20        | IM            | 30         | ↓ *         | ↑ ***| 13 m        | Suncion et al. (2014) | [31]   |
| NCT02323477    | Phase 1/2 | 20        | IM            | 79         | n.a.        | n.a. | 12 m        | Can et al. (2015) | [32]   |
| NCT00883727    | Phase 1/2 | 180–220   | IV            | 20         | =           | =   | 2 y         | Chullikana et al. (2015) | [33]   |
| NCT02504437    | Phase 1/2 | —         | —             | 200        | —           | —   | 12 m        | Pei (2015–2017)  | ClinicalTrials.gov |
| NCT02503280    | Phase 1/2 | 200       | —             | 55         | —           | —   | 12 m        | Joshua (2015–2032) | ClinicalTrials.gov |
| NCT02666391    | Phase 1/2 | —         | —             | 64         | —           | —   | 18 m        | Pei (2016–2017)  | ClinicalTrials.gov |
| NCT01770613    | Phase 2  | —         | —             | 124        | —           | —   | 12 m        | Nabil (2013–2017) | ClinicalTrials.gov |
| NCT00684021    | Phase 2  | 150        | IC            | 101        | n.a.        | ↑ ***| 6 m         | Schutt et al. (2015) | [34]   |
| NCT00984178    | Phase 2  | 15         | IC            | 120        | ↓ *         | ↑ **| 12 m        | Suncion et al. (2014) | [35]   |
| NCT0765453     | Phase 2  | 59.8       | IC            | 100        | n.a.        | ↑ ***| 12 m        | Choudry et al. (2015) | [36]   |
| NCT01293320    | Phase 2  | 6          | IC            | 116        | ↓ ***       | ↑ ***| 18 m        | Gao et al. (2015)  | [37]   |
| NCT03047772    | Phase 2  | —         | —             | 124        | —           | —   | 12 m        | Yang (2017–2018) | ClinicalTrials.gov |
| NCT00877903    | Phase 2  | —         | IV            | 220        | —           | —   | 5 y         | Donna (2009–2018) | ClinicalTrials.gov |
| NCT02013674    | Phase 2  | 100        | IM            | 30         | ↓ *         | ↑ *  | 12 m        | Florea et al. (2013–2019) | [38]   |
| NCT01392105    | Phase 2/3 | 72        | IC            | 80         | n.a.        | ↑ *  | 6 m         | Lee et al. (2014) | [39]   |
| NCT03404063    | Phase 2/3 | 30        | IC            | 115        | —           | —   | 6 m         | Piotr (2017–2020) | ClinicalTrials.gov |
| NCT01394432    | Phase 3  | —         | IM            | 50         | —           | —   | 12 m        | Evgeny (2012–2016) | ClinicalTrials.gov |
| NCT01652209    | Phase 3  | —         | IM            | 135        | —           | —   | 13 m        | Yang (2013–2020) | ClinicalTrials.gov |
| NCT02672267    | Phase 3  | —         | IM            | 50         | —           | —   | 6 m         | Saule (2014–2016) | ClinicalTrials.gov |

MSCs: mesenchymal stem cells; MI: myocardial infarction; IM: intramyocardial; IC: intracoronary; IV: intravenous; LVEF: left ventricular ejection fraction; y: year; m: month; n.a.: not analyzed; =: no statistical significance. *p < 0.05, **p < 0.01, and ***p < 0.001.
3.2. Genetic Modification and Cytokine/Drug Treatment on MSCs. To obtain enough cell numbers, MSC expansion in culture usually needs 1–3 months [5]. Not only is the process time-consuming and laborious but also it is difficult to maintain the multidifferentiation ability. Viral vectors or nonviral methods were used to genetically modify MSCs before transplantation. Overexpression of antiapoptotic transcription factor Akt could significantly increase MSC viability [54]. MSCs transfected with both OCT4 and SOX2 showed a strong proliferative activity [55]. Overexpressing manganese superoxide dismutase can endow cells with anoxic tolerance before transplantation then effectively increase the survival rate [56]. Studies that enhance cell engraftment via genetic modification are listed in Table 2. Pretreating MSCs with cytokines/drugs prior to transplantation can promote cell proliferation. A combination of hypoxia (5% O2) and 10 ng/mL basic fibroblast growth factor generated a significant synergistic effect. It produced highly reproducible MSCs, allowing MSCs to maintain multipotential differentiation ability after the 11th generation. Besides, the cell production is 2.8 times faster than the traditional method [57]. Chemical drugs are also used for MSC pretreatment. Proline hydroxylase inhibitor DMOG-pretreated MSCs significantly reduced cell mortality after transplantation, which is associated with elevated expressions of hypoxia-inducible factor-1α (HIF-1α), VEGF, GLUT-1, and phospho-Akt were significantly increased [58]. Mitochondrial electron transport inhibitors, such as antimycin, have been used to block the activation of mitochondrial death pathways [53]. Omentin-1 promotes MSC proliferation, inhibits apoptosis, increases the secretion of angiogenic cytokines, and enhances angiogenesis via the PI3K/Akt signaling pathway [59]. Studies that enhance cell engraftment via drug/cytokine pretreatment are listed in Table 3.

3.3. Cotransplantation MSCs with Bioactive Factors. Multiple studies have shown that cotherapy with drugs/specific cells/cytokines/specific biomaterials can prolong the survival time of MSCs and thus improve their therapeutic efficacy [117]. MSC transplantation combined with heparin significantly reduced the retention of MSCs in the lungs. Cotransplantation of MSCs and HGF improved cardiac function and reduced infarct size of post-MI heart [118]. Encapsulating cells in an injectable biomaterial could play an antioxidant role [119]. In a rat MI model, the survival rate of MSCs was increased by about 30% after coinjection with fibrin glue [120]. In a swine MI model, cotransplantation of MSCs and cardiac stem cells was reported to be superior than transplantation of each single type of stem cells [121]. Combined therapy of MSCs and rosuvastatin reduced fibrosis, decreased cardiomyocyte apoptosis, and preserved heart function [122]. Nutrient-rich plasma containing high levels of growth factors and secreted proteins has been identified as a biological material which can promote MSC function and promote wound healing. Thus, cotransplantation of MSCs with plasma is beneficial for MSCs adapting to nutritional deficiency in the infarct myocardium, which has been applied for clinical trials [123]. When we injected the MSCs through intravenous administration, it is easy to induce the block of vessels. Then, the use of vasodilator drugs significantly avoids the issues and contributes to the migration and homing of MSCs [53].

3.4. Biomaterials, Scaffolds, and Tissue Engineering to Improve MSC Functions. Long-term retention in the injection site is a necessary condition for the continued effectiveness of MSCs in the MI treatment. MSCs have multiple administration routes applied to clinical or preclinical studies. Injection routes including intravenous injection, intracoronary injection, intramyocardial injection (including transendocardial and transepicardial) were applied for MSC transplantation [124, 125]. Systematic intravenous injection is obviously simple and easy for dose control, but it causes massive cell redistribution into other organs such as the liver and lung. To date, intracoronary injection is the most studied technique during the time of percutaneous coronary intervention after MI, which is convenient and proved safe. Stem cells delivered through this method have been proved to improve cardiac function and reduce infarct size. Furthermore, specific studies comparing the effectiveness of different cell delivery routes showed that catheter-based transendocardial injection is superior to intracoronary injection, in terms of cell retention and cardiac function improvement [126]. Accumulating evidence supported that both transendocardial and surgical transepicardial injections are safe and effective in various preclinical and clinical studies [38]. Therefore, intramyocardial injection is considered to be the most efficient way for cell delivery [127]. However, even after intramyocardial delivery, the majority of transplanted cells are lost; thus, the above methods still could not guarantee the cell survival and long-term retention.

3.4.1. Multicellular Spheres. Cell preparations based on multicellular spheres have proved to be a promising way to enhance the therapeutic potential of MSCs [128]. Compared with the traditional two-dimensional (2D) monolayer culture, three-dimensional (3D) cell tissue can enhance the intracellular effect. Compared with the same number of MSCs in the traditional 2D monolayer culture, the MSC sphere in fibrin gel increased the level of VEGF secretion by 100 times [129] and the level of the CXCR4 receptor by 2 times [130]. The MSC sphere also obviously increases the expressions of HIF-1, FGF2, HGF, and miRNAs related to pleiotropia [17, 131]. Therefore, 3D MSCs improve the anti-inflammatory and angiogenic properties of MSCs after transplantation. In both rodent and porcine MI models, 3D MSCs were shown to be differentiated into endothelial cells and myocardium-like cells after transplantation and improve cardiac function of post-MI hearts [132, 133].

3.4.2. Cell Sheet and Hydrogels. Cell sheet technology has been confirmed to prolong the resident time of transplanted cells in the infarct myocardium [134]. The effect of three-layer MSC sheet administration for MI treatment is better than that of conventional intramyocardial injection [135]. The use of biomaterials, such as suspending MSCs in hydrogels or coated MSCs with hydrogel, may
effectively reduce the mechanical forces during injection and protect cells from damage [136].

The process of survival and retention of MSCs can be affected by various factors, such as ischemia, hypoxia, and inflammatory cell attack. The application of tissue engineering can improve this undesirable state [137]. The physical properties and microstructure of hydrogels regulate the infiltration of inflammatory cytokines and T lymphocytes in vivo, thereby reducing the attack of inflammatory cells on MSCs [53]. Injecting MSCs in an in situ cross-linked alginate hydrogel can maintain its activity and keep its paracrine with no immunogenicity [138]. Encapsulating MSCs in an alginate hydrogel patch may also improve the retention of MSCs [139]. The collagen scaffolds (such as type I collagen scaffolds) can enhance the adhesion and proliferation of MSCs and exhibit better cyto compatibility [4].

In addition, the invention of an artificial simulated extracellular matrix based on tissue engineering has overcome many difficulties in the application of MSCs. Using hydrogels as scaffolds and adding high-affinity growth factors and chemokines may overcome the loss of chemokines via cell-scaffold interaction [4, 140]. MSCs suspended at 2% sodium alginate (a natural hydrogel) before transplanting was four times more effective [141].

**Table 2: Gene modification in MSC transplantation for treating MI.**

| Gene name       | Disease | Model | Modification   | Gene function                  | Reference |
|-----------------|---------|-------|----------------|--------------------------------|-----------|
| Bcl2L1 (Bcl-xL) | MI, Rat | MSC culture | Overexpression | Apoptosis ↑; angiogenesis ↑ | [73]      |
| AKT1            | MI, Rat | MSC culture | Overexpression | Apoptosis ↑; cardiac function ↑ | [74]      |
| miR-23a         | MI, Rat | MSC culture | Overexpression | Apoptosis ↑; infarct size ↓ | [75]      |
| miR-7b          | MI, Rat | MSC culture | Overexpression | Cardiac function ↑; infarct size ↓; angiogenesis ↑ | [76]      |
| VEGF            | MI, Rat | MSC culture | Overexpression | Survival ↑; angiogenesis ↑ | [77]      |
| HIF-1A          | MI, Rat | MSC culture | Overexpression | Paracrine ↑; angiogenesis ↑; migration ↑ | [78]      |
| KLF1 (tissue kallikrein) | MI, Rat | MSC culture | Overexpression | Apoptosis ↑; apoptosis ↑ | [79]      |
| PHD2            | MI, Mouse | Silence | Overexpression | Survival ↑; apoptosis ↑; infarct size ↓ | [80]      |
| ecSOD           | MI, Mouse | Overexpression | Infarction size ↓; apoptosis ↑; survival ↑ | [81]      |
| MIR-1 (miR-1)   | MI, Mouse | Overexpression | Survival ↑ | [82]      |
| ILK             | MI, Porcine | Overexpression | Homing ↑; LVEF ↑; myocardial remodeling ↑ | [84]      |
| IGFBP-1         | MI, Porcine | Overexpression | Angiogenesis ↑ | [85]      |
| GLP-1           | MI, Porcine | Overexpression | Angiogenesis ↑ | [86]      |
| VEGF (165)      | MI, Ovine | Overexpression | Infarct size ↓; left ventricular function ↑ | [87]      |
| hRAMP1          | MI, Rabbit | Overexpression | Infarct size ↓ | [88]      |
| SOD2            | — | MSC culture | Overexpression | Apoptosis ↑ | [56]      |
| miR-210         | — | MSC culture | Overexpression | Apoptosis ↑; survival ↑ | [88]      |
| CXCL12          | — | MSC culture | Overexpression | Apoptosis ↑; proliferation ↑ | [89]      |

MDK: midkine; Trx1: thioredoxin-1; PKCε: protein kinase C ε; IGF-1: insulin-like growth factor-1; Hsp27: exogenous heat shock protein 27; SOD2: manganese superoxide dismutase; OH-1: heme oxygenase; CXXC4: CXXC chemokine receptor 4; CAMKK1: calcium/calmodulin-dependent protein kinase kinase; FGF4: fibroblast growth factor 4; bFGF: basic fibroblast growth factor; GLP: glucagon-like peptide; SIRT1: silent mating type information regulation 2 homolog 1; FGF4: fibroblast growth factor 4; miR: microRNA; MIR1-1: miR-1; PHD2: prolyl hydroxylase domain protein 2; GLP-1: glucagon-like peptide; SIRT1: silent mating type information regulation 2 homolog 1; FGF4: fibroblast growth factor 4; bFGF: basic fibroblast growth factor; ecSOD: extracellular superoxide dismutase; RAMP1: receptor activity-modifying protein 1; PKG1α: protein kinase type 1α.
3.4.3. Nanomaterials. Nanobiomaterial-incorporated stem cell therapy for MI has aroused much attention in recent years. The cardiac patch [142], nanofibrous scaffolds [143], and self-assembling peptides [144] appear promising in repairing the damaged myocardium. Cardiac patches consist of native collagen or synthetic polymers with a nanofibrous structure poly(lactide-co-epsilon caprolactone (PLCL)). These patches function when they are placed on the epicardial surface of the infarcted myocardium. PLCL is a highly flexible polymer which can form nanofibrous scaffolds, which significantly improves the survival rate of implanted MSCs compared to MSCs by direct injection [145]. Bioinspired self-assembling peptide nanofibers can be used as a cell carrier. MSCs that dealt with functional self-assembling peptide nanofibers RAD/PRG or RAD/KLT showed improved efficacy to treat MI [144]. Another study constructed poly(lactide-co-glycolide)-monomethoxy-poly(ethylene glycol) nanoparticles to encapsulate melatonin on adipose-derived MSCs and improve the efficiency of their transplantation [146].

3.5. Modifying Transplantation Environment of the Host Myocardium. Modifying the target tissue prior to MSC transplantation to make the environment more conducive is a supplement approach to donor cell pretreatment. C1q/tumor necrosis factor-related protein-9 (CTRP9) is a novel prosurvival cardiokine with a significantly downregulated expression after MI, which is critical in maintaining a healthy microenvironment facilitating stem cell engraftment in infarcted myocardial tissue. Overexpression of CTRP9 in the host myocardium significantly enhanced stem cell therapeutic efficacy [147].

The process of transporting MSCs to damaged tissue is called homing, which is the result of the interaction of multiple chemokines and their receptors. CXC chemokine receptor 4 (CXCR4) and SDF-1 play a key role in the homing.
MSCs are naturally capable of migrating to the injured area in the myocardium, but this feature is impaired because in vitro culture would induce the loss of the key homing receptor CXCR4 and other cellular signals. Releasing the adenoviruses carrying SDF-1α to increase the local concentration of SDF-1α in the injured myocardium could increase the homing of MSCs [90]. Combination of SDF-1 secretes from the infarct myocardium, and CXCR4 in MSCs can induce the migration of MSCs to the injured site [4]. Meanwhile, transfection of MSCs with CXCR4 overexpression vector increased the number of migrating MSCs by 3-fold [4].

3.6. Novel Approaches to Stimulate MSC Homing. Another intriguing method to increase the homing efficiency of MSCs is cell surface engineering, which is the temporary modification of the cell surface. These temporary changes help to improve the homing of MSCs without affecting viability, proliferation, adhesion, or differentiation of the transplanted cells [148]. In addition, the phage display approaches were used to screen MI-specific peptide sequences. In MI mouse models, four peptide sequences (CRPPR, CRKDKC, KSTRKS, and CARSKNKDC4) were identified. The number of homing MSCs was significantly increased by injecting MSCs coated with MI-specific homing peptide in treating MI, indicating that the use of homing peptide-coated MSCs is a promising method for the treatment of MI [149].

Except for molecular modification of MSCs, it has been found that radiation, ultrasound, electric field, or magnetic field can also promote homing. Within 4 hours of MI, treating the bone marrow with 804 nm wavelength and 1 J/cm² energy density can increase the survival, proliferation, and homing of MSCs [150]. The magnetic targeting technique (MTT) is based on the premagnetization of MSCs and then MSCs move in vivo with the aid of a magnetic field [151]. MTT allows a wider range of transplanted cells to reach the target tissue, providing a more efficient and sustained medium release without increasing the number of MSCs [152].

Figure 1: The procedures of MSC-based therapy, including donor selection, cell expansion, dosage, injection routes, homing, and target tissue modification. MSCs: mesenchymal stem cells.
4. Conclusion and Future Perspectives

Many strategies were developed to modify the MSCs as well as the transplantation microenvironment, which improve the survival, retention, homing, multidifferentiation capacity, and paracrine factors, thereby enhancing the outcome of MSC-based therapy against MI (Figure 1). The combination of certain methods may exert synergistic effects to improve the efficacy of MSC transplantation. Clinical trials have shown that MSC transplantation is feasible and safe for MI, and it does not increase the risk of adverse events. Although some approaches such as supplement with rosuvastatin are clinically safe [122], whether other methods to improve the MSC functions are safe when applying to patients is currently uncertain. Further optimizing these methods to achieve clinical safety and effectiveness is of great significance for stem cell therapy.

Abbreviations

MI: Myocardial infarction
MSCs: Mesenchymal stem cells
BM-MSCs: Bone marrow mesenchymal stem cells
LVEF: Left ventricular ejection fraction
LVSF: Left ventricular systolic function
VEGF: Vascular endothelial growth factor
HGF: Hepatocyte growth factor
IGF-1: Insulin-like growth factor-1
SDF-1: Stromal cell-derived factor-1
PEDF: Pigment epithelium-derived factor
bFGF: Basic fibroblast growth factor
RCTs: Randomized controlled trials
HIF-1α: Hypoxia inducible factor-1α.

Conflicts of Interest

The authors declare no potential conflict of interest.

Authors’ Contributions

Zhi Chen and Long Chen have contributed equally to the article. Zhi Chen and Long Chen searched references, analyzed data and drafted the manuscript. Wei Eric Wang and Chunyu Zeng revised the manuscript. We apologize to the many investigators whose work in this area could not be mentioned by us because of space limitations.

Acknowledgments

This study was supported by research grants from the National Natural Science Foundation of China (31730043), National Key Research and Development Project of China (2018YFC1312700), and Program of Innovative Research Team by the National Natural Science Foundation (81721001).

References

[1] GBD 2013 Mortality and Causes of Death Collaborators, “Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013,” Lancet, vol. 385, no. 9963, pp. 117–171, 2015.
[2] R. M. Samsonraj, M. Raghunath, V. Nurcombe, J. H. Hui, A. J. van Wijnen, and S. M. Cool, “Concise review: multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine,” Stem Cells Translational Medicine, vol. 6, no. 12, pp. 2173–2185, 2017.
[3] A. S. Go, D. Mozaffarian, V. L. Roger et al., “Heart Disease and Stroke Statistics—2014 Update: a report from the American Heart Association,” Circulation, vol. 129, no. 3, pp. e28–e292, 2014.
[4] S. T. Ji, H. Kim, J. Yun, J. S. Chung, and S. M. Kwon, “Promising therapeutic strategies for mesenchymal stem cell-based cardiovascular regeneration: from cell priming to tissue engineering,” Stem Cells International, vol. 2017, Article ID 3945403, 13 pages, 2017.
[5] F. Vizoso, N. Eiro, S. Cid, J. Schneider, and R. Perez-Fernandez, “Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine,” International Journal of Molecular Sciences, vol. 18, no. 9, p. 1852, 2017.
[6] C. Sanina and J. M. Hare, “Mesenchymal stem cells as a biological drug for heart disease: where are we with cardiac cell-based therapy?,” Circulation Research, vol. 117, no. 3, pp. 229–233, 2015.
[7] S. Lee, E. Choi, M. J. Cha, and K. C. Hwang, “Cell adhesion and long-term survival of transplanted mesenchymal stem cells: a prerequisite for cell therapy,” Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 632902, 9 pages, 2015.
[8] C. Miao, M. Lei, W. Hu, S. Han, and Q. Wang, “A brief review: the therapeutic potential of bone marrow mesenchymal stem cells in myocardial infarction,” Stem Cell Research & Therapy, vol. 8, no. 1, p. 242, 2017.
[9] B. Liu, C. Y. Duan, C. F. Luo et al., “Effectiveness and safety of selected bone marrow stem cells on left ventricular function in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials,” International Journal of Cardiology, vol. 177, no. 3, pp. 764–770, 2014.
[10] G. Maguire, “Stem cell therapy without the cells,” Communicative & Integrative Biology, vol. 6, no. 6, article e26631, 2014.
[11] T. Nagamura-Inoue and H. He, “Umbilical cord-derived mesenchymal stem cells: their advantages and potential clinical utility,” World Journal of Stem Cells, vol. 6, no. 2, pp. 195–202, 2014.
[12] F. S. Loffredo, M. L. Steinhauser, J. Gannon, and R. T. Lee, “Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair,” Cell Stem Cell, vol. 17, no. 1, p. 125, 2015.
[13] I. A. White, C. Sanina, W. Balkan, and J. M. Hare, “Mesenchymal stem cells in cardiology,” Methods in Molecular Biology, vol. 1416, pp. 55–87, 2016.
[14] W. E. Wang, D. Yang, L. Li et al., “Prolyl hydroxylase domain protein 2 silencing enhances the survival and paracrine function of transplanted adipose-derived stem cells in infarcted myocardium,” Circulation Research, vol. 113, no. 3, pp. 288–300, 2013.
[15] A. C. Pandey, J. J. Lancaster, D. T. Harris, S. Goldman, and E. Juneman, “Cellular therapeutics for heart failure: focus on mesenchymal stem cells,” Stem Cells International, vol. 2017, Article ID 9640108, 12 pages, 2017.

[16] T. Wen, L. Wang, X. J. Sun, X. Zhao, G. W. Zhang, and J. Li-Ling, “Sevoflurane preconditioning promotes activation of resident CSCs by transplanted BMSCs via miR-210 in a rat model for myocardial infarction,” Oncotarget, vol. 8, no. 70, pp. 114637–114647, 2017.

[17] L. Guo, Y. Zhou, S. Wang, and Y. Wu, “Epigenetic changes of mesenchymal stem cells in three-dimensional (3D) spheroids,” Journal of Cellular and Molecular Medicine, vol. 18, no. 10, pp. 2009–2019, 2014.

[18] A. Burlacu, G. Grigorescu, A. M. Rosca, M. B. Preda, and R. Li, X.-M. Li, and J.-R. Chen, “Factors secreted by mesenchymal stem cells and endothelial progenitor cells have complementary effects on angiogenesis in vitro,” Stem Cells and Development, vol. 22, no. 4, pp. 643–653, 2013.

[19] J. Y. Xu, D. Liu, Y. Zhong, and R. C. Huang, “Effects of timing on intracoronary autologous bone marrow-derived cell transplantation in acute myocardial infarction: a meta-analysis of randomized controlled trials,” Stem Cell Research & Therapy, vol. 8, no. 1, p. 231, 2017.

[20] R. Li, X.-M. Li, and J.-R. Chen, “Clinical efficacy and safety of autologous stem cell trans-plantation for patients with ST-segment elevation myocardial infarction,” Therapeutics and Clinical Risk Management, vol. 12, no. 1, pp. 1171–1189, 2016.

[21] H. Jeong, H. W. Yim, H.-J. Park et al., “Mesenchymal stem cell therapy for ischemic heart disease: systematic review and meta-analysis,” International Journal of Stem Cells, vol. 11, no. 1, pp. 1–12, 2018.

[22] J. M. Hare, J. H. Traverse, T. D. Henry et al., “A randomized, double-Blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction,” Journal of the American College of Cardiology, vol. 54, no. 24, pp. 2277–2286, 2009.

[23] M. S. Penn, S. Ellis, S. Gandhi et al., “Adventitial delivery of an allogeneic bone marrow derived adherent stem cell in acute myocardial infarction: phase I clinical study,” Circulation Research, vol. 110, no. 2, pp. 304–311, 2012.

[24] L. R. Gao, X. T. Pei, Q. A. Ding et al., “A critical challenge: dosage-related efficacy and acute complication intracoronary injection of autologous bone marrow mesenchymal stem cells in acute myocardial infarction,” International Journal of Cardiology, vol. 168, no. 4, pp. 3191–3199, 2013.

[25] J. H. Traverse, T. D. Henry, C. J. Pepine, J. T. Willerson, and S. G. Ellis, “One-year follow-up of intracoronary stem cell delivery on left ventricular function following ST-elevation myocardial infarction,” JAMA, vol. 311, no. 3, pp. 301–302, 2014.

[26] X. Hu, X. Huang, Q. Yang et al., “Safety and efficacy of intracoronary hypoxia preconditioned bone marrow mononuclear cell administration for acute myocardial infarction patients: the CHINA-AMI randomized controlled trial,” International Journal of Cardiology, vol. 184, pp. 446–451, 2015.

[27] J. M. Hare, J. E. Fishman, G. Gerstenblith et al., “Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transcatheter injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial,” JAMA, vol. 308, no. 22, pp. 2369–2379, 2012.

[28] V. Y. Suncion, E. Gershin, J. E. Fishman et al., “Does transcatheter injection of mesenchymal stem cells improve myocardial function locally or globally?,” Circulation Research, vol. 114, no. 8, pp. 1292–1301, 2014.

[29] A. Can, A. T. Ulus, O. Cinar et al., “Human umbilical cord mesenchymal stromal cell transplantation in myocardial ischemia (HUC-HEART Trial). A study protocol of a phase 1/2, controlled and randomized trial in combination with coronary artery bypass grafting,” Stem Cell Research and Reports, vol. 11, no. 5, pp. 752–760, 2015.

[30] A. Chullikana, A. S. Majumdar, S. Gottipamula et al., “Randomized, double-blind phase I/II study of intravenous allogeneic mesenchymal stromal cell injection in acute myocardial infarction,” Cytotherapy, vol. 17, no. 3, pp. 250–261, 2015.

[31] R. C. Schutt, B. H. Trachtenberg, J. P. Cooke et al., “Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial,” Circulation Research, vol. 116, no. 1, pp. 99–107, 2015.

[32] J. A. San Roman, P. L. Sánchez, A. Villa et al., “Comparison of different bone marrow–derived stem cell approaches in reperfused STEMI: a multicenter, prospective, randomized, open-labeled TECAM trial,” Journal of the American College of Cardiology, vol. 65, no. 22, pp. 2372–2382, 2015.

[33] F. Choudry, S. Hamshere, N. Saunders et al., “A randomized double-blind control study of early intra-coronary autologous bone marrow cell infusion in acute myocardial infarction: the REGENERATE-AMI clinical trial,” European Heart Journal, vol. 37, no. 3, pp. 256–263, 2016.

[34] L. R. Gao, Y. Chen, N. K. Zhang et al., “Intracoronary infusion of Wharton’s jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial,” BMC Medicine, vol. 13, no. 1, p. 162, 2015.

[35] V. Florea, A. C. Rieger, D. L. DiFede et al., “Dose comparison study of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy (The TRIDENT study),” Circulation Research, vol. 121, no. 11, pp. 1279–1290, 2017.

[36] J. W. Lee, S. H. Lee, Y. J. Youn et al., “A randomized, open-label, multicenter trial for the safety and efficacy of adult mesenchymal stem cells after acute myocardial infarction,” Journal of Korean Medical Science, vol. 29, no. 1, pp. 23–31, 2014.

[37] K. C. Elahi, G. Klein, M. Avci-Adali, K. D. Sievert, S. MacNeil, and W. K. Aicher, “Human mesenchymal stromal cells from different sources diverge in their expression of cell surface proteins and display distinct differentiation patterns,” Stem Cells International, vol. 2016, Article ID 5646384, 9 pages, 2016.
[41] H. Liang, H. Hou, W. Yi et al., “Increased expression of pigment epithelium-derived factor in aged mesenchymal stem cells impairs their therapeutic efficacy for attenuating myocardial infarction injury,” European Heart Journal, vol. 34, no. 22, pp. 1681–1690, 2013.

[42] N. Haque, M. T. Rahman, N. H. Abu Kasim, and A. M. Alabsi, “Hypoxic culture conditions as a solution for mesenchymal stem cell based regenerative therapy,” The Scientific World Journal, vol. 2013, Article ID 632972, 12 pages, 2013.

[43] G. Ren, X. Chen, F. Dong et al., “Concise review: mesenchymal stem cells and translational medicine: emerging issues,” Stem Cells Translational Medicine, vol. 1, no. 1, pp. 51–58, 2012.

[44] L. A. Marquez-Curtis and A. Janowska-Wiezorek, “Enhancing the migration ability of mesenchymal stromal cells by targeting the SDF-1/CXCR4 axis,” BioMed Research International, vol. 2013, Article ID 561098, 15 pages, 2013.

[45] A. A. Karpov, D. V. Udalova, M. G. Pliss, and M. M. Galagudza, “Can the outcomes of mesenchymal stem cell-based therapy for myocardial infarction be improved? Providing weapons and armour to cells,” Cell Proliferation, vol. 50, no. 2, article e12316, 2017.

[46] N. Haque, N. H. A. Kasim, and M. T. Rahman, “Optimization of pre-transplantation conditions to enhance the efficacy of mesenchymal stem cells,” International Journal of Biological Sciences, vol. 11, no. 3, pp. 324–334, 2015.

[47] X. Hu, Y. Xu, Z. Zhong et al., “A large-scale investigation of hypoxia-preconditioned allogeneic mesenchymal stem cells for myocardial repair in nonhuman primates: paracrine activity without remuscularization,” Circulation Research, vol. 118, no. 6, pp. 970–983, 2016.

[48] Y. Liu, X. Yang, P. Maureira et al., “Permanently hypoxic cell culture yields rat bone marrow mesenchymal cells with higher therapeutic potential in the treatment of chronic myocardial infarction,” Cellular Physiology and Biochemistry, vol. 44, no. 3, pp. 1064–1077, 2017.

[49] U. Saini, R. J. Gumina, B. Wolfe, M. L. Kuppusamy, P. Kuppusamy, and K. D. Boudoals, “Preconditioning mesenchymal stem cells with caspase inhibition and hyperoxia prior to hypoxia exposure increases cell proliferation,” Journal of Cellular Biochemistry, vol. 114, no. 11, pp. 2612–2623, 2013.

[50] J. Zhang, G. H. Chen, Y. W. Wang et al., “Hydrogen peroxide preconditioning enhances the therapeutic efficacy of Wharton’s Jelly mesenchymal stem cells after myocardial infarction,” Chinese Medical Journal, vol. 125, no. 19, pp. 3472–3478, 2012.

[51] P. F. Qiao, L. Yao, X. C. Zhang, G. D. Li, and D. Q. Wu, “Heat shock pretreatment improves stem cell repair following ischemia-reperfusion injury via autophagy,” World Journal of Gastroenterology, vol. 21, no. 45, pp. 12822–12834, 2015.

[52] A. Moya, N. Larochette, J. Paquet et al., “Quiescence preconditioned human multipotent stromal cells adopt a metabolic profile favorable for enhanced survival under ischemia,” Stem Cells, vol. 35, no. 1, pp. 181–196, 2017.

[53] S. Baldari, G. di Rocco, M. Piccoli, M. Pozzobon, M. Muraca, and G. Toietta, “Challenges and strategies for improving the regenerative effects of mesenchymal stromal cell-based therapies,” International Journal of Molecular Sciences, vol. 18, no. 10, 2017.

[54] A. Flynn, X. Chen, E. O’connell, and T. O’Brien, “A comparison of the efficacy of transplantation of bone marrow-derived mesenchymal stem cells and unrestricted somatic stem cells on outcome after acute myocardial infarction,” Stem Cell Research & Therapy, vol. 3, no. 5, p. 36, 2012.

[55] S. M. Han, S. H. Han, Y. R. Coh et al., “Enhanced proliferation and differentiation of Oct4- and Sox2-overexpressing human adipose tissue mesenchymal stem cells,” Experimental & Molecular Medicine, vol. 46, no. 6, article e101, 2014.

[56] S. Baldari, G. di Rocco, A. Trivisonno, D. Samengo, G. Pani, and G. Toietta, “Promotion of survival and engraftment of transplanted adipose tissue-derived stromal and vascular cells by overexpression of manganese superoxide dismutase,” International Journal of Molecular Sciences, vol. 17, no. 7, 2016.

[57] C. M. Caroti, H. Ahn, H. F. Salazar et al., “A novel technique for accelerated culture of murine mesenchymal stem cells that allows for sustained multipotency,” Scientific Reports, vol. 7, no. 1, article 13334, 2017.

[58] X.-B. Liu, J.-A. Wang, X.-Y. Ji, S. Yu, and L. Wei, “Preconditioning of bone marrow mesenchymal stem cells by prolyl hydroxylase inhibition enhances cell survival and angiogenesis in vitro and after transplantation into the ischemic heart of rats,” Stem Cell Research & Therapy, vol. 5, no. 5, p. 111, 2014.

[59] Z. Z. Wei, Y. B. Zhu, J. Y. Zhang et al., “Priming of the cells: hypoxic preconditioning for stem cell therapy,” Chinese Medical Journal, vol. 130, no. 19, pp. 2361–2374, 2017.

[60] L. M. McGinley, J. McMahon, A. Stocco et al., “Mesenchymal stem cell survival in the infarcted heart is enhanced by lentivirus vector-mediated heat shock protein 27 expression,” Human Gene Therapy, vol. 24, no. 10, pp. 840–851, 2013.

[61] Y. Chen, Y. Zhao, W. Chen et al., “MicroRNA-133 overexpression promotes the therapeutic efficacy of mesenchymal stem cells on acute myocardial infarction,” Stem Cell Research & Therapy, vol. 8, no. 1, p. 268, 2017.

[62] G. Su, L. Liu, L. Yang, Y. Mu, and L. Guan, “Homing of endogenous bone marrow mesenchymal stem cells to rat infarcted myocardium via ultrasound-mediated recombinant SDF-1α adenovirus in microbubbles,” Oncotarget, vol. 9, no. 1, pp. 477–487, 2018.

[63] F. Dong, S. Patnaik, Z. H. Duan, M. Kiedrowski, M. S. Penn, and M. E. Mayorga, “A novel role for CAMKK1 in the regulation of the mesenchymal stem cell secretome,” Stem Cells Translational Medicine, vol. 6, no. 9, pp. 1759–1766, 2017.

[64] L. Chen, Y. Zhang, L. Tao, Z. Yang, and L. Wang, “Mesenchymal stem cells with eNOS over-expression enhance cardiac repair in rats with myocardial infarction,” Cardiovascular Drugs and Therapy, vol. 31, no. 1, pp. 9–18, 2017.

[65] L. Wang, Z. Pasha, S. Wang et al., “Protein kinase G1 α over-expression increases stem cell survival and cardiac function after myocardial infarction,” PLoS One, vol. 8, no. 3, article e60087, 2013.

[66] Y. Liang, Q. Lin, J. Zhu et al., “The caspase-8 shRNA-modified mesenchymal stem cells improve the function of infarcted heart,” Molecular and Cellular Biochemistry, vol. 397, no. 1–2, pp. 7–16, 2014.

[67] X. Liu, H. Chen, W. Zhu et al., “Transplantation of SIRT1-engineered aged mesenchymal stem cells improves cardiac function in a rat myocardial infarction model,” The Journal of Heart and Lung Transplantation, vol. 33, no. 10, pp. 1083–1092, 2014.

[68] T. Ke, Y. Wu, L. Li et al., “Nitrin-1 ameliorates myocardial infarction-induced myocardial injury: mechanisms of action..."
in rats and diabetic mice,” Human Gene Therapy, vol. 25, no. 9, pp. 787–797, 2014.

[69] X. Q. Chen, L. L. Chen, L. Fan, J. Fang, Z. Y. Chen, and W. W. Li, “Stem cells with FGFR4-bFGF fused gene enhances the expression of bFGF and improves myocardial repair in rats,” Biochemical and Biophysical Research Communications, vol. 447, no. 1, pp. 145–151, 2014.

[70] Z. Wen, W. Huang, Y. Feng et al., “MicroRNA-377 regulates mesenchymal stem cell-induced angiogenesis in ischemic hearts by targeting VEGF,” PLoS One, vol. 9, no. 9, article e104666, 2014.

[71] H. He, Z. H. Zhao, F. S. Han, X. H. Liu, R. Wang, and Y. J. Zeng, “Overexpression of protein kinase Cε improves retention and survival of transplanted mesenchymal stem cells in rat acute myocardial infarction,” Cell Death and Disease, vol. 7, no. 1, article e2056, 2016.

[72] C. J. Yang, J. Yang, J. Yang, and Z. X. Fan, “Thioredoxin-1 (Trx1) engineered mesenchymal stem cell therapy is a promising feasible therapeutic approach for myocardial infarction,” International Journal of Cardiology, vol. 206, pp. 169–170, 2016.

[73] X. Xue, Y. Liu, J. Zhang, T. Liu, Z. Yang, and H. Wang, “Bcl-xl genetic modification enhanced the therapeutic efficacy of transplanted mesenchymal stem cells in rat myocardial infarction,” Stem Cells International, vol. 2015, Article ID 176409, 14 pages, 2015.

[74] S. L. Zhao, Y. J. Zhang, M. H. Li, X. L. Zhang, and S. L. Chen, “Mesenchymal stem cells with overexpression of midkine enhance cell survival and attenuate cardiac dysfunction in a rat model of myocardial infarction,” Stem Cell Research & Therapy, vol. 5, no. 2, p. 37, 2014.

[75] J. Mao, Z. Lv, and Y. Zhuang, “MicroRNA-23a is involved in tumor necrosis factor-α-induced apoptosis in mesenchymal stem cells and myocardial infarction,” Experimental and Molecular Pathology, vol. 97, no. 1, pp. 23–30, 2014.

[76] O. Ham, S. Y. Lee, C. Y. Lee et al., “Let-7b suppresses apoptosis and autophagy of human mesenchymal stem cells transplanted into ischemia/reperfusion injured heart 7 by targeting caspase-3,” Stem Cell Research & Therapy, vol. 6, no. 1, p. 147, 2015.

[77] H. H. Moon, M. K. Joo, H. Mok et al., “MSC-based VEGF gene therapy in rat myocardial infarction model using facial amphipathic bile acid-conjugated polyethyleneimine,” Biomaterials, vol. 35, no. 5, pp. 1744–1754, 2014.

[78] I. Cerrada, A. Ruiz-Sauri, R. Carrero et al., “Hypoxia-inducible factor 1 alpha contributes to cardiac healing in mesenchymal stem cells-mediated cardiac repair,” Stem Cells and Development, vol. 22, no. 3, pp. 501–511, 2013.

[79] L. Gao, G. Bledsoe, H. Yin, B. Shen, L. Chao, and J. Chao, “Tissue kalikrein-modified mesenchymal stem cells provide enhanced protection against ischemic cardiac injury after myocardial infarction,” Circulation Journal, vol. 77, no. 8, pp. 2134–2144, 2013.

[80] K. Zhu, H. Lai, C. Guo et al., “Novel vector-based prolyl hydroxylase domain 2 silencing system enhances the efficiency of stem cell transplantation for infarcted myocardium repair,” International Journal of Nanomedicine, vol. 9, pp. 5203–5215, 2014.

[81] Q. Pan, X. Qin, S. Ma et al., “Myocardial protective effect of extracellular superoxide dismutase gene modified bone marrow mesenchymal stromal cells on infarcted mice hearts,” Theranostics, vol. 4, no. 5, pp. 475–486, 2014.

[82] F. Huang, M. L. Li, Z. F. Fang et al., “Overexpression of MicroRNA-1 improves the efficacy of mesenchymal stem cell transplantation after myocardial infarction,” Cardiology, vol. 125, no. 1, pp. 18–30, 2013.

[83] L. Zhao, X. Liu, Y. Zhang et al., “Enhanced cell survival and paracrine effects of mesenchymal stem cells overexpressing hepatocyte growth factor promote cardioprotection in myocardial infarction,” Experimental Cell Research, vol. 344, no. 1, pp. 30–39, 2016.

[84] Q. Mao, C. Lin, J. Gao et al., “Mesenchymal stem cells overexpressing integrin-linked kinase attenuate left ventricular remodeling and improve cardiac function after myocardial infarction,” Molecular and Cellular Biochemistry, vol. 397, no. 1–2, pp. 203–214, 2014.

[85] G. Gómez-Mauricio, I. Moscoso, M.-F. Martín-Cancho et al., “Combined administration of mesenchymal stem cells overexpressing IGF-1 and HGF enhances neovascularization but moderately improves cardiac regeneration in a porcine model,” Stem Cell Research & Therapy, vol. 7, no. 1, p. 94, 2016.

[86] R. de Jong, G. P. J. van Hout, J. H. Houtgraaf et al., “Intracoronary infusion of encapsulated glucagon-like peptide-1-eluting mesenchymal stem cells preserves left ventricular function in a porcine model of acute myocardial infarction,” Circulation. Cardiovascular Interventions, vol. 7, no. 5, pp. 673–683, 2014.

[87] P. Locatelli, F. D. Olea, A. Hnatiuk et al., “Mesenchymal stromal cells overexpressing vascular endothelial growth factor in ovine myocardial infarction,” Gene Therapy, vol. 22, no. 6, pp. 449–457, 2015.

[88] J. Xu, Z. Huang, L. Lin et al., “miR-210 over-expression enhances mesenchymal stem cell survival in an oxidative stress environment through antioxidation and c-Met pathway activation,” Science China Life Sciences, vol. 57, no. 10, pp. 989–997, 2014.

[89] C. Xiaowei, M. Jia, W. Xiaowei, and Z. Yina, “Overexpression of CXCL12 chemokine up-regulates connexin and integrin expression in mesenchymal stem cells through PI3K/Akt pathway,” Cell Communication & Adhesion, vol. 20, no. 3–4, pp. 67–72, 2013.

[90] J. Hou, L. Wang, J. Hou et al., “Peroxisome proliferator-activated receptor gamma promotes mesenchymal stem cells to express connexin43 via the inhibition of TGF-β1/Smads signaling in a rat model of myocardial infarction,” Stem Cell Reviews, vol. 11, no. 6, pp. 885–899, 2015.

[91] N. Li, J. Y. Yang, H. Y. Qian et al., “Intravenous administration of atorvastatin-pretreated mesenchymal stem cells improves cardiac performance after acute myocardial infarction role of CXCR4,” American Journal of Translational Research, vol. 7, no. 6, pp. 1058–1070, 2015.

[92] I. Elmadbouh and M. Ashraf, “Tadalafl, a long acting phosphodiesterase inhibitor, promotes bone marrow stem cell survival and their homing into ischemic myocardium for cardiac repair,” Physiological Reports, vol. 5, no. 21, article e13480, 2017.

[93] X. Gong, “Protective effect of ailanthus excelsa roxb in myocardial infarction post mesenchymal stem cell transplantation: study in chronic ischemic rat model,” African Journal of Traditional, Complementary, and Alternative Medicines, vol. 13, no. 6, pp. 155–162, 2016.

[94] X. Liu, D. Hu, Z. Zeng et al., “SRT1720 promotes survival of aged human mesenchymal stem cells via FAIM: a pharmacological strategy to improve stem cell-based therapy for rats
myocardial infarction,” *Cell Death & Disease*, vol. 8, no. 4, article e2731, 2017.

[95] C. Liu, Y. Fan, L. Zhou et al., “Pretreatment of mesenchymal stem cells with angiotensin II enhances paracrine effects, angiogenesis, gap junction formation and therapeutic efficacy for myocardial infarction,” *International Journal of Cardiology*, vol. 188, pp. 22–32, 2015.

[96] H. D. Guo, G. H. Cui, J. X. Tian et al., “Transplantation of sialic acid B pretreated mesenchymal stem cells improves cardiac function in rats with myocardial infarction through angiogenesis and paracrine mechanisms,” *International Journal of Cardiology*, vol. 177, no. 2, pp. 538–542, 2014.

[97] I. Khan, A. Ali, M. A. Akhter et al., “Preconditioning of mesenchymal stem cells with 2,4-dinitrophenol improves cardiac function in infarcted rats,” *Life Sciences*, vol. 162, pp. 60–69, 2016.

[98] G. W. Zhang, T. X. Gu, X. J. Sun et al., “Edaravone promotes activation of resident cardiac stem cells by transplanted mesenchymal stem cells in a rat myocardial infarction model,” *The Journal of Thoracic and Cardiovascular Surgery*, vol. 152, no. 2, pp. 570–582, 2016.

[99] H. Xu, G. Zhu, and Y. Tian, “Protective effects of trimetazidine on bone marrow mesenchymal stem cells viability in an *ex vivo* model of hypoxia and *in vivo* model of locally myocardial ischemia,” *Journal of Huazhong University of Science and Technology. Medical Sciences*, vol. 32, no. 1, pp. 36–41, 2012.

[100] J. Guo, D. Zheng, W. F. Li, H. R. Li, A. D. Zhang, and Z. C. Li, “Insulin-like growth factor 1 treatment of MSCs attenuates inflammation and cardiac dysfunction following MI,” *Inflammation*, vol. 37, no. 6, pp. 2156–2163, 2014.

[101] C.-M. Wang, Z. Guo, Y. J. Xie et al., “Co-treating mesenchymal stem cells with IL-1β and TNF-α increases VCAM-1 expression and improves post-ischemic myocardial function,” *Molecular Medicine Reports*, vol. 10, no. 2, pp. 792–798, 2014.

[102] Y.-L. Liu, Y. Zhou, L. Sun et al., “Protective effects of ginkgo biloba extract 761 on myocardial infarction via improving the viability of implanted mesenchymal stem cells in the rat heart,” *Molecular Medicine Reports*, vol. 9, no. 4, pp. 1112–1120, 2014.

[103] L. Ye, P. Zhang, S. Duval, L. Su, Q. Xiong, and J. Zhang, “Thymosin β4 increases the potency of transplanted mesenchymal stem cells for myocardial repair,” *Circulation*, vol. 128, 11, Supplement 1, pp. S32–S41, 2013.

[104] J. Xie, H. Wang, T. Song et al., “Tanshinone IIA and aristagloside IV promote the migration of mesenchymal stem cells by up-regulation of CXCR4,” *Protoplasma*, vol. 250, no. 2, pp. 521–530, 2013.

[105] D. Han, W. Huang, X. Li et al., “Melatonin facilitates adipose-derived mesenchymal stem cells to repair the murine infarcted heart via the SIRT1 signaling pathway,” *Journal of Pineal Research*, vol. 60, no. 2, pp. 178–192, 2016.

[106] D. I. Cho, W. S. Kang, M. H. Hong et al., “The optimization of cell therapy by combinational application with apicidin-treated mesenchymal stem cells after myocardial infarction,” *Oncotarget*, vol. 8, no. 27, pp. 44281–44294, 2017.

[107] W. Lu, Z. Xie, Y. Tang et al., “Photoluminescent mesoporous silicon nanoparticles with siCCR2 improve the effects of mesenchymal stromal cell transplantation after acute myocardial infarction,” *Theranostics*, vol. 5, no. 10, pp. 1068–1082, 2015.

[108] F. Franchi, A. Ezenekwe, L. Wellkamp, K. M. Peterson, A. Lerman, and M. Rodriguez-Porcel, “Renin inhibition improves the survival of mesenchymal stromal cells in a mouse model of myocardial infarction,” *Journal of Cardiovascular Translational Research*, vol. 7, no. 6, pp. 560–569, 2014.

[109] L. Song, Y. J. Yang, Q. T. Dong et al., “Aprotinin enhances efficacy of mesenchymal stem cells treatment for swine myocardial infarction via activation of nitric oxide synthase,” *PLoS One*, vol. 8, no. 5, article e65702, 2013.

[110] W. T. Hsu, H. Y. Jui, Y. H. Huang et al., “CXCR4 antagonist TG-0054 mobilizes mesenchymal stem cells, attenuates infarction, and preserves cardiac systolic function in a porcine model of myocardial infarction,” *Cell Transplantation*, vol. 24, no. 7, pp. 1313–1328, 2015.

[111] E. J. Wright, N. W. Hodson, M. J. Sherratt et al., “Combined MSC and GLP-1 therapy modulates collagen remodeling and apoptosis following myocardial infarction,” *Stem Cells International*, vol. 2016, Article ID 7357096, 12 pages, 2016.

[112] J. Yang, J. Xia, Y. He, J. Zhao, and G. Zhang, “MSCs transplantation with application of G-CSF reduces apoptosis or increases VEGF in rabbit model of myocardial infarction,” *Cytotechnology*, vol. 67, no. 1, pp. 27–37, 2015.

[113] Z. Qu, H. Xu, Y. Tian, and X. Jiang, “Aprotinin stimulates microenvironment to enhance the beneficial effects of BMSCs therapy in a rabbit model of acute myocardial infarction,” *Cellular Physiology and Biochemistry*, vol. 32, no. 2, pp. 380–389, 2013.

[114] F. Zhang, J. Cui, B. Lv, and B. Yu, “Nicorandil protects mesenchymal stem cells against hypoxia and serum deprivation-induced apoptosis,” *International Journal of Molecular Medicine*, vol. 36, no. 2, pp. 415–423, 2015.

[115] D. Huang, L. Yin, X. Liu et al., “Geraniin protects bone marrow-derived mesenchymal stem cells against hydrogen peroxide-induced cellular oxidative stress in vitro,” *International Journal of Molecular Medicine*, vol. 41, no. 2, pp. 739–748, 2017.

[116] H. Zhou, D. Li, C. Shi et al., “Effects of extendin-4 on bone marrow mesenchymal stem cell proliferation, migration and apoptosis in vitro,” *Scientific Reports*, vol. 5, no. 1, p. 12898, 2015.

[117] F. Pourrajab, M. Babaie Zarch, M. Baghi Yazdi, A. Rahimi Zarchi, and A. Vakili Zarch, “Application of stem cell/growth factor system, as a multimodal therapy approach in regenerative medicine to improve cell therapy yields,” *International Journal of Cardiology*, vol. 173, no. 1, pp. 12–19, 2014.

[118] H. Yukawa, M. Watanabe, N. Kaji et al., “Monitoring transplanted adipose tissue-derived stem cells combined with heparin in the liver by fluorescence imaging using quantum dots,” *Biomaterials*, vol. 33, no. 7, pp. 2177–2186, 2012.

[119] B. R. Dollinger, M. K. Gupta, J. R. Martin, and C. L. Duvall, “Reactive oxygen species shielding hydrogel for the delivery of adherent and nonadherent therapeutic cell types,” *Tissue Engineering Part A*, vol. 23, no. 19-20, pp. 1120–1131, 2017.

[120] D. Sürder, R. Manka, T. Moccetti et al., “Effect of bone marrow-derived mononuclear cell treatment, early or late after acute myocardial infarction: twelve months CMR and long-term clinical results,” *Circulation Research*, vol. 119, no. 3, pp. 481–490, 2016.

[121] G. Lamirault, S. Susen, V. Forest et al., “Difference in mobilization of progenitor cells after myocardial infarction in smoking versus non-smoking patients: insights from the...
S. Golpanian, I. H. Schulman, R. F. Ebert et al., "Rosuvastatin enhances the therapeutic efficacy of adipose-derived mesenchymal stem cells for myocardial infarction via PI3K/Akt and MEK/ERK pathways," Basic Research in Cardiology, vol. 108, no. 2, p. 333, 2013.

M. Tobita, S. Tajima, and H. Mizuno, "Peptide hydrogel enables instant epicardial coating of the heart after myocardial infarction: combination of biomaterials, tissue engineering for cartilage regeneration?," Stem Cell Research & Therapy, vol. 7, no. 1, p. 56, 2016.

B. Assmus, D. M. Leistner, V. Schächinger et al., "Long-term clinical outcome after intracoronary application of bone marrow-derived mononuclear cells for acute myocardial infarction: migratory capacity of administered cells determines event-free survival," European Heart Journal, vol. 35, no. 19, pp. 1275–1283, 2014.

B. A. Aguado, W. Mulyasasmita, J. Su, K. J. Lampe, and S. C. Heilshorn, "Improving viability of stem cells during syringe needle flow through the design of hydrogel cell carriers," Tissue Engineering. Part A, vol. 18, no. 7-8, pp. 806–815, 2012.

J. C. Bernhard and G. Vunjak-Novakovic, "Should we use cells, biomaterials, or tissue engineering for cartilage regeneration?," Stem Cell Research & Therapy, vol. 7, no. 1, p. 56, 2016.
mesenchymal stem cell," *Journal of Drug Targeting*, vol. 20, no. 1, pp. 23–32, 2011.

[150] Z. H. El Gammal, A. M. Zaher, and N. El-Badri, “Effect of low-level laser-treated mesenchymal stem cells on myocardial infarction,” *Lasers in Medical Science*, vol. 32, no. 7, pp. 1637–1646, 2017.

[151] L. Li, S. Wu, Z. Liu et al., “Ultrasound-targeted microbubble destruction improves the migration and homing of mesenchymal stem cells after myocardial infarction by upregulating SDF-1/CXCR4: a pilot study,” *Stem Cells International*, vol. 2015, Article ID 691310, 14 pages, 2015.

[152] Z. Huang, Y. Shen, A. Sun et al., “Magnetic targeting enhances retrograde cell retention in a rat model of myocardial infarction,” *Stem Cell Research & Therapy*, vol. 4, no. 6, p. 149, 2013.